MQS Management’s Haemonetics HAE Stock Holding History

MQS Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,352	Closed	-$287K	–	552
2023 Q4	$287K	Buy	+3,352	New	+$290K	0.16%	278

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MQS Management's HAE Position: Q1 2024 in Review

MQS Management sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 3,352 shares — an estimated $287K sold.

MQS Management first reported a position in HAE in Q4 2023 and held it in 1 quarter. The position peaked at $287K in Q4 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

MQS Management reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
MQS Management sold 3,352 Haemonetics shares in Q1 2024, an estimated $287K.
MQS Management first reported a position in Haemonetics in Q4 2023 and held it in 1 quarter.
MQS Management's Haemonetics position peaked at $287K in Q4 2023.
298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on MQS Management's 13F filing for Q1 2024, filed 14 May 2024.